As a pharmaceutical company driven by innovative R&D and committed to synergistic innovation, Simcere highly value the significance of becoming a global company, which enables access to wider market and opportunities to form synergy with lots of excellent partners world-wide.
We are happy to have formed alliance with Almirall on Sept 29 2022. This IL-2 out-licensing deal has caught wide spread attention by media not only in China but also in the Asia-Pacific area as well as the American and European regions. Here's a shot of a few of them:
Biospace
Simcere closed an out-license deal of 492M USD with Almirall
Oct 06, 2022
https://www.biospace.com/article/simcere-closed-an-out-license-deal-of-492m-usd-with-almirall/
Business Mirror
Simcere closes out-license deal of with Almirall worth 492M USD
OCTOBER 13, 2022 by BMPLUS）
https://businessmirror.com.ph/2022/10/13/simcere-closes-out-license-deal-of-with-almirall-worth-492m-usd/
Bloomberg
Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc
Published on 09 29 2022 by Business Wire
www.Bloomberg.com/press-releases/2022-09-29/almirall-and-simcere-enter-into-a-licensing-agreement-for-il-2-mu-fc
日经BP社：
スペインAlmirall社、中国Simcere社からTregを活性化するIL-2医薬を導入
2022.10.11 by 川俣佐惠
https://bio.nikkeibp.co.jp/atcl/news/p1/22/10/04/10001/
Fierce pharma
https://www-fiercepharma-com/pharma/eisai-biogen-alzheimers-win-astellas-pfizer-patent-right-novartis-sandoz-plant-sale
Endpoint News
Almirall partners up with Simcere in potential $500M+ deal — with plans to take IL-2 candidate global
09 29, 2022 by Paul Schloesser
https://endpts.com/almirall-partners-up-with-simcere-in-potential-500m-deal-with-plans-to-take-il-2-candidate-global/
Biospectrum Asia
Simcere, Almirall ink $492 M deal for treating autoimmune diseases
29 September 2022
https://www.biospectrumasia.com/news/26/21142/simcere-almirall-ink-492-m-deal-for-treating-autoimmune-diseases.html
Bioworld（总部伦敦）
Simcere out-licenses autoimmune drug to Almirall in $507M deal
29 September 2022
https://www.bioworld.com/articles/690107-almirall-and-simcere-enter-licensing-agreement-for-il-2-mu-fc-sim-0278-for-autoimmune-diseases?v=preview
Almirall and Simcere enter licensing agreement for IL-2 mu-Fc SIM-0278 for autoimmune diseases
Oct. 4, 2022 by Doris Yu
https://www.bioworld.com/articles/690256-simcere-out-licenses-autoimmune-drug-to-almirall-in-507m-deal?v=preview
APnews
Simcere agree license deal of $492M USD with Almirall
October 8, 2022 by EIN Presswire | Newsmatics
https://apnews.com/press-release/ein-presswire-newsmatics/science-health-hong-kong-greater-china-macau-7c1cf45a7a4470ec99ae772868134d31
BambooWORKS：
FAST NEWS: Simcere Pharmaceutical Grants Overseas Rights for Drug Candidate
0930 2022 by Jony Ho
The pharma letter
Simcere to pocket potential $507 million in Almirall deal
29-09-202
https://www.thepharmaletter.com/article/simcere-to-pocket-potential-507-million-in-almirall-deal
Pharmaboardroom
Almirall USD 507 million deal with Simcere for its IL-2 drug (Press Release)
https://pharmaboardroom.com/articles/china-pharma-news-moderna-steadfast-on-mrna-ip-advanced-medtech-buys-wikkon-menarini-sciclone-amr-deal/
Informa Pharma Intelligence
Asia Deal Watch: Astellas Seeks Pantherna’s Assistance On mRNA-Based Regenerative Medicine，Plus deals involving OliPass/Vanda, Simcere/Almirall, Sinopharm/Merck & Co., Jiuzhou/Sandoz, Zai Lab/Seagen, Sciwind/SynderK, Hansoh/KiOmed.
by Joseph Haas、Ian Haydock、Jung Won Shin
https://scrip.pharmaintelligence.informa.com/SC147180/Asia-Deal-Watch-Astellas-Seeks-Panthernas-Assistance-On-mRNA-Based-Regenerative-Medicine
PipelineReview.com
Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc
29 September 2022
European Business Review
Simcere Closed an Out-License Deal of 492M USD with Almirall
October 19, 2022
https://www.europeanbusinessreview.com/simcere-closed-an-out-license-deal-of-492m-usd-with-almirall/
The Marketwatch
Simcere closed an out-license deal of 492M USD with Almirall
Published: Oct. 12, 2022
https://www.marketwatch.com/press-release/simcere-closed-an-out-license-deal-of-492m-usd-with-almirall-2022-10-12?mod=search_headline
